Drug-eluting stents are now routinely used in the treatment of acute coronary syndromes caused by coronary artery disease. Whilst the sustained release of anti-proliferative drugs from these devices has greatly reduced the need for repeat revascularisation procedures, this approach is not suitable for all patients and appears to delay regrowth of the endothelium, necessitating the use of prolonged dual anti-platelet therapy. Although the development of more advanced stent platforms and drug coatings has produced modest improvements in performance, these devices have not fully addressed the limitations experienced with their first-generation counterparts. In the present study, we developed a novel stent coating that provides controlled sirolimus release from a bioactive polymer (accelerate™ AT) that has previously been shown to support endothelial cell growth in vitro. A bespoke electrospray deposition process provided control over the coating thickness, surface roughness, drug load, and release kinetics. The resultant optimised coating combines rapid release of an anti-proliferative agent from a bioactive polymer coating that promotes re-endothelialisation, thereby offering potential protection against in-stent restenosis and thrombosis. This novel, dual-action coating therefore has significant therapeutic potential, with the enhanced control of drug load and release kinetics offered by electrospray deposition also opening up opportunities for more personalised treatment approaches. Further development and evaluation of these technologies in vitro and in vivo is therefore warranted.

中文翻译：

---

生物活性高分子药物洗脱冠状动脉支架涂层的电喷雾技术开发

现在，药物洗脱支架通常用于治疗由冠状动脉疾病引起的急性冠状动脉综合症。尽管从这些装置中持续释放抗增殖药已大大减少了重复血运重建程序的需要，但这种方法并不适合所有患者，并且似乎会延迟内皮的再生长，因此需要使用延长的双重抗血小板治疗。尽管开发更先进的支架平台和药物涂层在性能上产生了适度的改善，但是这些设备尚未完全解决第一代同类产品所遇到的限制。在目前的研究中，体外。定制的电喷雾沉积工艺可控制涂层厚度，表面粗糙度，载药量和释放动力学。所得的优化涂层结合了抗增殖剂从生物活性聚合物涂层中的快速释放，从而促进了内皮的再内皮化，从而提供了针对支架内再狭窄和血栓形成的潜在保护。因此，这种新颖的双作用涂层具有巨大的治疗潜力，通过电喷雾沉积所提供的增强的药物负荷控制和释放动力学，也为更多个性化的治疗方法提供了机会。因此，需要在体外和体内对这些技术进行进一步的开发和评估。